2024-11-272025-12-312025-12-31false16104924BAIHE MEDICAL (UK) LTD2026-08-1732500falseiso4217:GBPxbrli:pure161049242024-11-26161049242025-12-31161049242024-11-272025-12-31161049242024-11-25161049242024-11-26161049242024-11-262024-11-2616104924bus:SmallEntities2024-11-272025-12-3116104924bus:AuditExempt-NoAccountantsReport2024-11-272025-12-3116104924bus:FullAccounts2024-11-272025-12-3116104924bus:PrivateLimitedCompanyLtd2024-11-272025-12-3116104924core:WithinOneYear2025-12-3116104924core:AfterOneYear2025-12-3116104924core:WithinOneYear2024-11-2616104924core:AfterOneYear2024-11-2616104924core:ShareCapital2025-12-3116104924core:SharePremium2025-12-3116104924core:RevaluationReserve2025-12-3116104924core:OtherReservesSubtotal2025-12-3116104924core:RetainedEarningsAccumulatedLosses2025-12-3116104924core:ShareCapital2024-11-2616104924core:SharePremium2024-11-2616104924core:RevaluationReserve2024-11-2616104924core:OtherReservesSubtotal2024-11-2616104924core:RetainedEarningsAccumulatedLosses2024-11-2616104924core:LandBuildings2025-12-3116104924core:PlantMachinery2025-12-3116104924core:Vehicles2025-12-3116104924core:FurnitureFittings2025-12-3116104924core:OfficeEquipment2025-12-3116104924core:NetGoodwill2025-12-3116104924core:IntangibleAssetsOtherThanGoodwill2025-12-3116104924core:ListedExchangeTraded2025-12-3116104924core:UnlistedNon-exchangeTraded2025-12-3116104924core:LandBuildings2024-11-2616104924core:PlantMachinery2024-11-2616104924core:Vehicles2024-11-2616104924core:FurnitureFittings2024-11-2616104924core:OfficeEquipment2024-11-2616104924core:NetGoodwill2024-11-2616104924core:IntangibleAssetsOtherThanGoodwill2024-11-2616104924core:ListedExchangeTraded2024-11-2616104924core:UnlistedNon-exchangeTraded2024-11-2616104924core:LandBuildings2024-11-272025-12-3116104924core:PlantMachinery2024-11-272025-12-3116104924core:Vehicles2024-11-272025-12-3116104924core:FurnitureFittings2024-11-272025-12-3116104924core:OfficeEquipment2024-11-272025-12-3116104924core:NetGoodwill2024-11-272025-12-3116104924core:IntangibleAssetsOtherThanGoodwill2024-11-272025-12-3116104924core:ListedExchangeTraded2024-11-272025-12-3116104924core:UnlistedNon-exchangeTraded2024-11-272025-12-3116104924core:MoreThanFiveYears2024-11-272025-12-3116104924core:Non-currentFinancialInstruments2025-12-3116104924core:Non-currentFinancialInstruments2024-11-2616104924dpl:CostSales2024-11-272025-12-3116104924dpl:DistributionCosts2024-11-272025-12-3116104924core:LandBuildings2024-11-272025-12-3116104924core:PlantMachinery2024-11-272025-12-3116104924core:Vehicles2024-11-272025-12-3116104924core:FurnitureFittings2024-11-272025-12-3116104924core:OfficeEquipment2024-11-272025-12-3116104924dpl:AdministrativeExpenses2024-11-272025-12-3116104924core:NetGoodwill2024-11-272025-12-3116104924core:IntangibleAssetsOtherThanGoodwill2024-11-272025-12-3116104924dpl:GroupUndertakings2024-11-272025-12-3116104924dpl:ParticipatingInterests2024-11-272025-12-3116104924dpl:GroupUndertakingscore:ListedExchangeTraded2024-11-272025-12-3116104924core:ListedExchangeTraded2024-11-272025-12-3116104924dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-11-272025-12-3116104924core:UnlistedNon-exchangeTraded2024-11-272025-12-3116104924dpl:CostSales2024-11-262024-11-2616104924dpl:DistributionCosts2024-11-262024-11-2616104924core:LandBuildings2024-11-262024-11-2616104924core:PlantMachinery2024-11-262024-11-2616104924core:Vehicles2024-11-262024-11-2616104924core:FurnitureFittings2024-11-262024-11-2616104924core:OfficeEquipment2024-11-262024-11-2616104924dpl:AdministrativeExpenses2024-11-262024-11-2616104924core:NetGoodwill2024-11-262024-11-2616104924core:IntangibleAssetsOtherThanGoodwill2024-11-262024-11-2616104924dpl:GroupUndertakings2024-11-262024-11-2616104924dpl:ParticipatingInterests2024-11-262024-11-2616104924dpl:GroupUndertakingscore:ListedExchangeTraded2024-11-262024-11-2616104924core:ListedExchangeTraded2024-11-262024-11-2616104924dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2024-11-262024-11-2616104924core:UnlistedNon-exchangeTraded2024-11-262024-11-2616104924core:NetGoodwill2025-12-3116104924core:IntangibleAssetsOtherThanGoodwill2025-12-3116104924core:LandBuildings2025-12-3116104924core:PlantMachinery2025-12-3116104924core:Vehicles2025-12-3116104924core:FurnitureFittings2025-12-3116104924core:OfficeEquipment2025-12-3116104924core:AfterOneYear2025-12-3116104924core:WithinOneYear2025-12-3116104924core:ListedExchangeTraded2025-12-3116104924core:UnlistedNon-exchangeTraded2025-12-3116104924core:ShareCapital2025-12-3116104924core:SharePremium2025-12-3116104924core:RevaluationReserve2025-12-3116104924core:OtherReservesSubtotal2025-12-3116104924core:RetainedEarningsAccumulatedLosses2025-12-3116104924core:NetGoodwill2024-11-2616104924core:IntangibleAssetsOtherThanGoodwill2024-11-2616104924core:LandBuildings2024-11-2616104924core:PlantMachinery2024-11-2616104924core:Vehicles2024-11-2616104924core:FurnitureFittings2024-11-2616104924core:OfficeEquipment2024-11-2616104924core:AfterOneYear2024-11-2616104924core:WithinOneYear2024-11-2616104924core:ListedExchangeTraded2024-11-2616104924core:UnlistedNon-exchangeTraded2024-11-2616104924core:ShareCapital2024-11-2616104924core:SharePremium2024-11-2616104924core:RevaluationReserve2024-11-2616104924core:OtherReservesSubtotal2024-11-2616104924core:RetainedEarningsAccumulatedLosses2024-11-2616104924core:NetGoodwill2024-11-2516104924core:IntangibleAssetsOtherThanGoodwill2024-11-2516104924core:LandBuildings2024-11-2516104924core:PlantMachinery2024-11-2516104924core:Vehicles2024-11-2516104924core:FurnitureFittings2024-11-2516104924core:OfficeEquipment2024-11-2516104924core:AfterOneYear2024-11-2516104924core:WithinOneYear2024-11-2516104924core:ListedExchangeTraded2024-11-2516104924core:UnlistedNon-exchangeTraded2024-11-2516104924core:ShareCapital2024-11-2516104924core:SharePremium2024-11-2516104924core:RevaluationReserve2024-11-2516104924core:OtherReservesSubtotal2024-11-2516104924core:RetainedEarningsAccumulatedLosses2024-11-2516104924core:AfterOneYear2024-11-272025-12-3116104924core:WithinOneYear2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:CostValuation2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-272025-12-3116104924core:Non-currentFinancialInstrumentscore:CostValuation2025-12-3116104924core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2025-12-3116104924core:Non-currentFinancialInstrumentscore:CostValuation2024-11-2616104924core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-11-2616104924core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-11-2616104924bus:Director12024-11-272025-12-3116104924bus:Director22024-11-272025-12-31

BAIHE MEDICAL (UK) LTD

Registered Number
16104924
(England and Wales)

Unaudited Financial Statements for the Period ended
31 December 2025

BAIHE MEDICAL (UK) LTD
Company Information
for the period from 27 November 2024 to 31 December 2025

Directors

HUANG, Kai
WU, Xiujuan

Registered Address

22 Rokesby Close
Welling
DA16 3RR

Registered Number

16104924 (England and Wales)
BAIHE MEDICAL (UK) LTD
Statement of Financial Position
31 December 2025

Notes

2025

£

£

Current assets
Stocks313,973
Debtors43,944
Cash at bank and on hand108,056
125,973
Creditors amounts falling due within one year5(22,771)
Net current assets (liabilities)103,202
Total assets less current liabilities103,202
Net assets103,202
Capital and reserves
Called up share capital100,000
Profit and loss account3,202
Shareholders' funds103,202
The financial statements were approved and authorised for issue by the Board of Directors on 17 August 2026, and are signed on its behalf by:
HUANG, Kai
Director
WU, Xiujuan
Director

Registered Company No. 16104924
BAIHE MEDICAL (UK) LTD
Notes to the Financial Statements
for the period ended 31 December 2025

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in compliance with FRS 102 Section 1A, as it applies to the financial statements for the period and there were no material departures from the reporting standard.
Revenue from sale of goods
Revenue from the sale of goods is recognised when the company has transferred to the buyer the significant risks and rewards of ownership of the goods, usually when goods are delivered and legal title has passed. Providing the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the company and the costs incurred or to be incurred in respect of the transition can be measured reliably.
Stocks and work in progress
Stock is valued at the lower of cost and estimated selling price less costs to complete and sell. The cost methodology employed by the entity is the first-in first-out method. Estimated selling price less costs to complete and sell are derived from the selling price which the goods would fetch in an open market transaction with established customers less the costs expected to be incurred to enable the sale to complete. Provision is made for slow-moving and obsolete items of stock. Such provisions are recognised in profit or loss. Work in progress is valued using the percentage of completion method and values are calculated using the lower of cost and estimated selling price less costs to complete and sell. When stocks are sold, the carrying amount of those stocks is recognised as an expense within cost of sales. This takes place in the same period that the associated revenue is recognised.
Trade and other debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Cash and cash equivalents
Cash and cash equivalents comprise cash at bank and on hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less.
Trade and other creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Share capital
Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of new ordinary shares or options are shown in equity as a deduction, net of tax, from the proceeds.
Related parties
For the purposes of these financial statements, a related party could be a person or an entity. Careful consideration is given to the definition of a related party to ensure that all related party relationships, transactions and balances are identified.
2.Average number of employees

2025
Average number of employees during the year1
3.Stocks

2025

£
Other stocks13,973
Total13,973
4.Debtors: amounts due within one year

2025

£
Trade debtors / trade receivables3,944
Total3,944
5.Creditors: amounts due within one year

2025

£
Trade creditors / trade payables20,927
Taxation and social security1,750
Other creditors94
Total22,771